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We have analysed the expression and cellular localisation of the matrix protein VP40 from Ebola virus. Full-length VP40 and
an N-terminal truncated construct missing the first 31 residues [VP40(31–326)] both locate to the plasma membrane of 293T
cells when expressed transiently, while a C-terminal truncation of residues 213 to 326 [VP40(31–212)] shows only expression
in the cytoplasm, when analysed by indirect immunofluorescence and plasma membrane preparations. In addition, we find
that full-length VP40 [VP40(1–326)] and VP40(31–326) are both released into the cell culture supernatant and float up in
sucrose gradients. The efficiency of their release, however, is dependent on the presence of the N-terminal 31 residues. VP40
that is released into the supernatant is resistant to trypsin digestion, a finding that is consistent with the formation of viruslike
particles detected by electron microscopy. Together, these results provide strong evidence that Ebola virus VP40 is sufficient
for virus assembly and budding from the plasma membrane. © 2001 Academic PressINTRODUCTION
Ebola virus and Marburg virus (Filoviridae) are non-
segmented negative-strand RNA viruses (Mononegavi-
rales) that cause severe hemorrhagic fever in humans
(1–3). The matrix protein VP40 is a major structural pro-
tein from Ebola virus and is thought to play a key role in
virus assembly and release, which takes place at the
plasma membrane (4, 5). Viral matrix proteins are multi-
functional proteins that interact with cellular membranes
and viral components such as the cytoplasmic tails of
glycoproteins as well as the ribonucleoprotein particle
(RNP) (6) in a process which triggers the formation and
the release of infectious particles from infected cells. The
Ebola virus matrix protein binds preferentially to lipo-
somes containing high amounts of negatively charged
phospholipids in vitro (7). A similar in vitro membrane
association behaviour has been observed for matrix pro-
teins from vesicular stomatitis virus (VSV) (8) and influ-
enza virus (9) as well as retroviral matrix proteins (10).
Ebola virus VP40 is a monomer in solution, consisting of
two domains (11). The C-terminal domain is absolutely
required for membrane association in vitro and the re-
moval of most of the C-terminal domain by trypsin diges-
tion has been shown to induce hexamerisation of VP40
(7). The same hexamerisation pattern is observed when
destabilizing the interdomain region by mutagenesis or
by urea treatment in vitro as well as by binding of VP40
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1to liposomes (12). Although it has been shown that the
VSV matrix protein is released from cells in the form of
lipid vesicles (13, 14), the efficiency of assembly and
particle release depends on interactions with cellular
proteins mediated by a conserved WW domain binding
motif (PPXY; PY motif) (15). A similar PY motif is found at
the N-terminus of Ebola virus VP40 where it mediates the
interaction with a ubiquitin ligase in a process which
was proposed to be important in budding (16). In con-
trast, most viral matrix proteins do not trigger the release
of vesicles from cells and virus-particle formation in-
volves multiple interactions (17–20). Here we demon-
strate that the matrix protein VP40 from Ebola virus
associates with the plasma membrane in vivo. This is
dependent on the presence of the C-terminal domain but
is not affected by the removal of the N-terminal PY motif.
Both findings are in agreement with data obtained in vitro
on VP40 membrane association (7). In addition, we show
that VP40 is released into the cell culture supernatant
when expressed by itself and is found associated with
lipid vesicles, which resemble filovirus-like particles as
determined by electron microscopy. However, the effi-
ciency of particle release is approximately fivefold de-
creased upon deletion of the proposed WW-domain bind-
ing motif, consistent with recently published findings
(16). This suggests that, on its own, VP40 is able to bud
through the plasma membrane and thus contains impor-
tant properties for the assembly and the release of Ebola
virus particles.Results. Ebola virus VP40 consists of two domains that
form a closed conformation in solution (Fig. 1) (11). The
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omain-binding motif as indicated which is not present in the crystal structure.
2 RAPID COMMUNICATIONN-terminal part, which is not present in the crystal struc-
ture, contains a PY motif (15). We transfected 293T cells
with cDNAs corresponding to VP40(1–326), VP40(31–
326), and VP40(31–212) (Fig. 1) to determine their cellular
localisation. Both VP40(1–326) and VP40(31–326) are ex-
pressed throughout the cytoplasm but concentrate in
patches along the plasma membrane as seen by indirect
immunofluorescence (Figs. 2A and 2B). In contrast, the
C-terminally truncated construct VP40(31–212) does not
localise to the plasma membrane and shows only diffuse
distribution throughout the cytoplasm (Fig. 2C). No stain-
ing can be seen with nontransfected or mock-transfected
cells (data not shown). These results were confirmed by
the analysis of plasma membrane preparations derived
from transfected 293T cells expressing VP40(1–326),
VP40(31–326), and VP40(31–212). Full-length VP40 mi-
grates at approximately 36 kDa, the N-terminal truncated
form slightly faster and C-terminally truncated VP40 mi-
grates at approximately 25 kDa when analysed by SDS–
PAGE and Western blotting (Fig. 3). Both constructs,
VP40(1–326) and VP40(31–326), associate with the
plasma membrane (Fig. 3A). Comparison of the total
protein expressed (Fig. 3A, lanes 1 and 3) and the
amount found to interact with the plasma membrane,
shows approximately 7% membrane association for both
constructs (Fig. 3B, lanes 2 and 4). This indicates that the
first 31 residues of VP40 are dispensable for its cellular
localisation and does not affect the efficiency of mem-
brane association, similar to the results obtained in vitro
(7). Deletion of most of the C-terminal domain of VP40
resulted in solely cytoplasmic expression of VP40(31–
212) and no protein was detected to be associated with
the plasma membrane (Fig. 3A, lanes 5 and 6), which
confirms the role of the C-terminal domain in membrane
targeting in vivo. This is also consistent with the immu-
nofluorescence staining (Fig. 2C) and liposome binding
assays performed in vitro (7).
Western blot analysis of the expression pattern of all
three constructs analysed indicates that full-length
FIG. 1. VP40 contains two structurally related domains that are indica
structure of VP40 (11). The N-terminal domain contains a potential WW d
VP40 constructs used for expression are shown.ted schematically. The two domains are shown as boxes based on the crystalVP40(1–326) as well as VP40(31–326) are both released
into the cell culture medium (Fig. 3B, lanes 1s and 3s).FIG. 2. Intracellular distribution of VP40 constructs and ADAM12-L
determined by indirect immunofluorescence. 293T cells, transfected
with pVP40(1–326) (A), with pVP40(31–326) (B), with pVP40(31–212) (C),
as well as with pADAM12-L (D), were fixed in methanol/acetone 72 h
posttransfection. VP40 was detected with a rabbit polyclonal antiserum
and ADAM12-L with a myc-tag specific mAb and fluorescein-conju-
gated secondary antibodies. Cells were observed under a 1003 oil
immersion objective with a Zeiss Axioscope microscope.
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3RAPID COMMUNICATIONTwenty-three percent of full-length VP40 is detected in
the cell culture supernatant when compared to the total
amount of protein expressed; however, only 5% of total
VP40(31–326) is released (Fig. 3B; lanes 3s and 4c). The
release of VP40(31–326) indicates a specific role for the
N-terminus containing the PY motif. The loss of mem-
brane targeting activity of VP40(31–212) is also consis-
tent with no release of VP40(31–212) missing most of the
C-terminal domain (Fig. 3B, lanes 5s and 6c). To further
substantiate that the presence of VP40 in the superna-
tant is not due to the release of protein by cell lysis, 293T
cells were also transfected with a full-length clone of
ADAM12-L, a type I membrane protein (21). Transfections
of all four constructs were done in parallel, and no
significant cell death was observed at the time of har-
vesting the cells and the supernatants. ADAM12-L is
clearly expressed at the cell surface of 293T cells as
expected (Fig. 2D) and an expression band correspond-
FIG. 3. (A) Plasma membrane preparations of VP40 expressed in
293T cells. Lanes 1 and 3 correspond to the total amount of VP40(1–
326) and VP40(31–326) expressed from 2 3 105 293T cells (100%).
anes 2 and 4 correspond to the amount of VP40(1–326) and VP40(31–
26) found to be associated with the plasma membrane compared to
he total amount (7% in each case). In contrast, VP40(31–212) does not
ssociate with the plasma membrane; lane 5, VP40(31–212) expressed
rom 4 3 105 cells (100%) compared to lane 6, plasma membrane
fraction corresponding to 4 3 105 cells (0%). (B) Western blot analysis
of VP40 expression in 293T cells. Cells were lysed 72 h posttransfec-
tion and cell extracts (c) and cell culture supernatants (s) were sepa-
rated on 12% SDS–PAGE; lanes 1s and 2c, VP40(1–326); lanes 3s and
4c, VP40(31–326); lanes 5s and 6c, VP40(31–212); and lanes 7s and 8c,
ADAM12L. VP40-specific bands were visualised using a VP40-specific
polyclonal antiserum and the anti-myc antibody was used to detect
ADAM12-L by Western blot analysis. Quantification of released VP40
indicates that 5% of VP40(31–326) and 23% of VP40(1–326) are released
into the culture medium when compared to total cell lysates (100%).
Molecular weight markers are indicated in kilodaltons.ing to the correct molecular weight can be seen in a
whole-cell extract but not in the cell culture supernatant
C
o(Fig. 3B, lanes 7 and 8). These data suggest that specific
membrane association of VP40(1–326) and VP40(31–326)
is necessary for the release of VP40 into the medium.
This interaction does not occur with VP40 expressed
only in the cytoplasm [such as VP40(31–212)] nor with a
plasma membrane anchored protein such as ADAM12-L,
as expected.
The supernatants of cells transfected with VP40 con-
structs were further analyzed by sucrose gradient cen-
trifugation. These results show that VP40(1–326) (Fig. 4A)
as well as VP40(31–326) (Fig. 4B) migrate toward the top
in a discontinuous sucrose gradient and most of the
protein is found in fractions 4 to 6 or 3 to 5 (Figs. 4A and
4B). Some protein remains in the bottom fractions 8 and
9 (Figs. 4A and 4B). Therefore, both VP40 proteins prob-
ably float with vesicles in upper fractions containing
20–30% sucrose. Trypsin digestion of vesicle-bound
VP40(1–326) also indicates that it is protected from pro-
teolysis. Incubation of VP40(1–326) derived from fraction
4 of the sucrose gradient (Fig. 4A) with trypsin showed
no proteolysis (Fig. 4C; lane 2). However, solubilisation of
VP40 from the same sucrose gradient fraction with Triton
X-100 shows that detergent treatment renders VP40 sen-
sitive to trypsin, resulting in smaller proteolytic products
(Fig. 4C, lane 3). Electron microscopy of vesicles re-
leased into the cell culture supernatant containing
VP40(1–326) and purified by sucrose gradient centrifu-
gation reveals the presence of filamentous viruslike par-
ticles. A typical particle shows a diameter of approxi-
mately 80 nm and a length of 1000 nm (Fig. 4D). This
suggests further that VP40 assembles at the plasma
membrane in a process which is capable of pinching off
vesicles that resemble viruslike structures.
Discussion. Viral matrix proteins exert their fundamen-
tal role in assembly and budding through their interac-
tion with cellular membranes. We have previously char-
acterised the in vitro binding properties of three soluble
forms of the Ebola virus matrix protein VP40 which
showed that (i) the N-terminal 31 residues were dispens-
able for membrane association; (ii) the C-terminal resi-
dues 213 to 326 were absolutely necessary for mem-
brane targeting; (iii) the removal of the C-terminal domain
led to hexamerisation of VP40(31–212) (7); and (iv) the
same hexamerisation pattern can be induced by urea
treatment, deletion of seven C-terminal residues, and
liposome binding in vitro (12). The structure of VP40 is
composed of two domains that are only weakly associ-
ated with each other and we have proposed that a
movement of the C-terminal domain induces hexameri-
sation of VP40 upon membrane association (11, 12). Here
we show that all three VP40 forms show the same mem-
brane binding properties in vivo as observed in vitro (7),
hereas membrane association absolutely requires the
-terminal domain. Interestingly, only a small percentage
f VP40, VP40(1–326) as well as VP40(31–326), is asso-
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4 RAPID COMMUNICATIONciated with the plasma membrane in mammalian cells. In
addition, our data suggest that VP40, when associated
with the plasma membrane, is released into the cell
culture supernatant. Sucrose floatation experiments with
the cell culture supernatant insinuate that VP40 is asso-
ciated with lipid vesicles. The protection from trypsin
digestion further suggests that VP40 is inside the vesi-
FIG. 4. Sucrose gradient floatation analysis of VP40 released into the
ell culture medium; (A) VP40(1–326) and (B) VP40(31–326). Fractions 8
nd 9 are part of the bottom fractions which were adjusted to 50%
ucrose while fractions 3 to 6 show that most of the released VP40
loats up in the gradient. Fractions from the sucrose gradient were
recipitated with TCA and separated on 12% SDS–PAGE. (C) Trypsin
igestion of VP40(1–326) found to be associated with lipid vesicles
fraction 4 corresponding to lane 4; Fig. 4A); lane 1, no trypsin; lane 2,
0 ng trypsin; lane 3, solubilisation of vesicles with 1% Triton X-100 and
0 ng trypsin. Full-length VP40 (lanes 1 and 3) and proteolytic products
lane 3) are indicated by arrows. VP40 samples were separated on 15%
DS–PAGE and specific bands were detected by Western blot analysis.
olecular weight markers are indicated. (D) Detection of filovirus-like
articles by negative staining electron microscopy. The black bar rep-
esents 100 nm. The diameter of the particle is approximately 80 nm
nd the length of the filamentous structure shown is approximately
000 nm.cles. Negative staining electron microscopy provides ad-
ditional evidence that vesicles, which bud off the plasma
a
smembrane, resemble viruslike structures. However, we
only detect viruslike particles at a very low efficiency,
which probably underlines an important role of other viral
proteins in particle formation (17–20, 22). Filovirus show
a uniform diameter of approximately 80 nm with some
variation in length (23). These measurements are in
agreement with the sizes of the observed filamentous
particles released from 293T cells expressing full-length
VP40(1–326) or VP40(31–326) (data not shown). Overall,
our experiments show that VP40 is able to assemble into
particles, most likely at the plasma membrane, which
can bud off the membrane. The resulting particles are
probably internally lined with VP40, in a process that can
be achieved in the absence of any other viral protein.
A similar release of vesicles containing matrix protein
has been reported for VSV, another member of the
Mononegavirales (13–15, 24). VSV M also contains a
putative WW domain binding motif (PY motif), which has
been suggested to bind to cellular factor(s) which en-
hance the function of M in assembly and particle release
(15). Ebola virus VP40 has a similar motif at its N-termi-
nus (15) and a recent paper by Harty et al. (16) shows that
the PY motif is important for budding and confers VP40’s
interaction with Rsp5, a ubiquitin ligase known to func-
tion in endocytosis in yeast and in mammalian cells
(Nedd4, mammalian homolog of Rsp5). Our finding that
the deletion of the complete PY motif sequence
[VP40(31–326)] still supports budding albeit to a fivefold
decreased efficiency is in agreement with the mutagen-
esis data of the PY motif which abolished the binding to
the ubiquitin ligase and reduced the release of vesicles
fourfold (16). Interestingly, ubiquitin has also been re-
cently implicated to play an important role in the retrovi-
ral budding machinery (25, 26) indicating a common
mechanism for particle release for retroviruses, filovi-
ruses, and rhabdoviruses. In addition, we provide evi-
dence that the deletion of the PY motif-containing se-
quence does not affect membrane association of VP40
implied by the same percentage of VP40 found to be
associated with the plasma membrane in vivo for full-
length VP40 as well as for VP40(31–326). These findings
are consistent with the data obtained in vitro with the
iposome binding assays (7).
Although we attempted to determine the oligomeric
tate of VP40 present in the vesicles released from cells,
hemical cross-linking experiments generally resulted in
igh molecular weight bands whose interpretation was
ot conclusive (data not shown) and could not be clearly
elated to the hexamers observed in vitro (12). However,
he formation of particles driven by the matrix protein
ndirectly infers the assembly of higher molecular weight
tructures by VP40 which eventually provide the archi-
ecture for particle release. The release of viruslike par-
icles containing VP40 provides evidence that VP40 is
ble to “self-assemble” on its own into a higher order
tructure on membranes, a feature which seems to be a
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5RAPID COMMUNICATIONprerequisite for membrane-containing particle formation.
The efficiency of such a process is dependent on the
interaction with cellular protein(s) (16) and the presence
of other viral proteins will most likely enhance the as-
sembly and budding efficiency. Nevertheless, our report
and a recent paper by Harty et al. (16) show that VP40
contains the minimal information necessary to induce
release of VP40-containing viruslike particles from mam-
malian cells.
Materials and Methods. Expression constructs. cDNAs
corresponding to full-length VP40, VP40 residues 31 to
326 [VP40(31–326)], and residues 31 to 212 [VP40(31–
212)] were cloned into the mammalian expression vector
pcDNA 3.1 (Invitrogen) [pVP40(1–326); pVP40(31–326);
pVP40(31–212)] and the cDNA corresponding to full-
length ADAM12-L (21) was cloned into the pSectagB
ector (Invitrogen) [pADAM12-L] using standard PCR
ethods. The correctness of the sequence of each con-
truct was verified by DNA sequencing. The ADAM12-L
onstruct contains a C-terminal myc-epitope.
Cell Line and Transfection. The 293T cells were grown
n DMEM medium supplemented with Glutamax I and
500 mg/ml glucose, 50 unit/ml penicillin, 50 mg/ml
streptomycin, and 10% fetal bovine serum (Life Technol-
ogies, Inc.) at 37°C and 5% CO2. 293T cells were grown
to 50% confluence and then transfected with 1 mg of
plasmid DNA mixed with 5 ml of Lipofectine (Life Tech-
ologies, Inc.). Cells and supernatants were collected 3
ays posttransfection for further analysis. Whole-cell ly-
ates (2 3 105 cells per lane) and supernatants (corre-
ponding to 2 3 105 cells) were analyzed by Western blot
using a VP40 specific antiserum as primary antibody and
a secondary anti-rabbit IgG serum conjugated to alkaline
phosphatase (Promega). The relative amount of total
expressed VP40 (set to be 100%) was compared to the
amount released by scanning the intensity of the bands
derived from the same amounts of total cells analysed.
Immunofluorescence. Cells were grown on cover
glasses and were analyzed by indirect immunofluores-
cence 3 days posttransfection. Cells were washed 3
times with cold PBS on ice containing 1 mM MgCl2 and
0.1 mM CaCl2 and subsequently permeabilised and fixed
with a solution containing ice-cold methanol (80%) and
acetone (20%) for 20 min at 220°C. Cells were then
blocked with PBS containing 1% BSA for 30 min before
being incubated with the primary antibody, a rabbit anti-
VP40 serum, or an anti-myc monoclonal antibody (Invitro-
gen) for 1 h at room temperature. Cells were washed 3
times with cold PBS containing 1 mM MgCl2 and 0.1 mM
CaCl2 before the secondary antibody conjugated with
luorescein-isothiocyanate, an anti-rabbit IgG (VP40), or
nti-mouse IgG (ADAM-12L) (Life Technologies, Inc.) was
dded. Cover glasses were mounted in fluoromount-G
Southern Biotechnology Associates, Inc.) and fluores- wence staining was visualised using an Axioskop fluo-
escence microscope (Zeiss).
Membrane Floatation Experiments. Cell culture super-
atants of transfected cells were made 50% sucrose
w/v) in a total volume of 5 ml. This was successively
verlaid with 2 ml of 40% sucrose (w/v), 2 ml of 35%
ucrose (w/v), 2 ml of 20% sucrose (w/v), and 1 ml of 10%
ucrose (w/v); all sucrose solutions were prepared in
BS. Gradients were centrifuged using a SW41 rotor at
0,000 rpm for 15 h at 12°C. Seven fractions of 1 ml and
wo 2.5-ml fractions from the bottom were collected from
he gradients and 500 ml of each fraction was precipi-
ated with 3.5% TCA for Western blot analysis. Pellets of
ach sample were separated on a 12% SDS–PAGE and
lotted onto nitrocellulose membranes. VP40 specific
ands were visualised by Western blot analysis as de-
cribed.
Trypsin Digestion. Fifty microliters of fraction 4 from
he sucrose gradient containing VP40(1–326) vesicles
Fig. 4A) were incubated with 50 ng trypsin for 1 h at
7°C in PBS buffer or in PBS buffer containing 1% Triton
-100 to solubilise VP40 contained in lipid vesicles. Sam-
les were separated on a 15% SDS–PAGE and VP40
pecific bands were detected by Western blot analysis
sing the amplified Opti-4CN detection kit (Bio-Rad).
Plasma Membrane Preparation. Plasma membranes
PM) were isolated using an isoosmotic homogenisation
edium (adapted from Ref. 27). Seventy-two hours post-
ransfection the cells were washed and detached in PBS
n ice. Cells were pelleted and then resuspended in
omogenisation buffer (HB) consisting of 0.25 M su-
rose, 10 mM Tris pH 7.4, and 1 mM MgCl2. A mixture of
protease inhibitors (Boehringer Mannheim) was also
added to the buffer. The cells were homogenised in a
Dounce homogeniser and nuclei were harvested by cen-
trifugation at 280 g for 10 min. The organelles and
lasma membranes were then pelleted at 1500 g for 10
in. This pellet was resuspended in HB before mixing it
ith 2 vol of 2 M sucrose in 10 mM Tris pH 7.4 and 1 mM
gCl2. This mixture was then overlaid with HB and the
embranes were purified by ultracentrifugation in a
W41 rotor at 24,000 rpm for 1 h at 4°C. The fraction
orresponding to the plasma membranes floated up to
he interface. This fraction was collected and diluted 10
imes in HB before harvesting the membranes by cen-
rifugation at 3000 g for 10 min. The membranes were
hen resuspended in SDS–sample buffer for Western blot
nalysis. Total VP40 protein derived from 2 3 105 cells
100%) and protein floating with the membrane fraction
orresponding to 2 3 105 cells were then separated on
5% SDS–PAGE and their relative quantity was deter-
ined by scanning the intensity of the bands.Electron Microscopy. Protein samples in PBS buffer
ere applied to the clean side of carbon on mica (car-
22
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6 RAPID COMMUNICATIONbon/mica interface) and negatively stained with methyl-
amine vanadate, CH3NH2VO3 (“NanoVan,” Nanoprobes,
Inc., Stony Brook, NY) (pH 8.0). Micrographs were taken
under low-dose conditions with a Jeol 1200 EX II micro-
scope at 100 kV and a nominal magnification of 40,0003.
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